Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006).
about
Gene therapy for severe combined immunodeficiency: are we there yet?Autoimmune dysregulation and purine metabolism in adenosine deaminase deficiency.Emerging PEGylated drugs.Concise review: lessons learned from clinical trials of gene therapy in monogenic immunodeficiency diseases.Increased adenosine contributes to penile fibrosis, a dangerous feature of priapism, via A2B adenosine receptor signalingAdenosine deaminase enzyme therapy prevents and reverses the heightened cavernosal relaxation in priapismToward 'SMART' stem cells.Development of gene therapy: potential in severe combined immunodeficiency due to adenosine deaminase deficiency.Towards a rAAV-based gene therapy for ADA-SCID: from ADA deficiency to current and future treatment strategies.How I treat ADA deficiency.Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID).Preclinical demonstration of lentiviral vector-mediated correction of immunological and metabolic abnormalities in models of adenosine deaminase deficiency.Primary immunodeficiency diseases: relevant aspects for pulmonologists.Update on the safety and efficacy of retroviral gene therapy for immunodeficiency due to adenosine deaminase deficiency.Gene therapy for primary immune deficiencies: a Canadian perspective.Expanded newborn screening by mass spectrometry: New tests, future perspectives.Severe combined immunodeficiency--an update.High-yield production of apoplast-directed human adenosine deaminase in transgenic tobacco BY-2 cell suspensions.Long-Term Outcome of Adenosine Deaminase-Deficient Patients-a Single-Center Experience.Diagnosis, Treatment and Long-Term Follow Up of Patients with ADA Deficiency: a Single-Center Experience.Poly(ethylene glycol)-Prodrug Conjugates: Concept, Design, and ApplicationsExpression of a functional human adenosine deaminase in transgenic tobacco plants.Newborn screening for severe combined immunodeficiency: an opportunity for intervention.Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety.A 9-yr evaluation of carrier erythrocyte encapsulated adenosine deaminase (ADA) therapy in a patient with adult-type ADA deficiency.Adenosine deaminase production by an endophytic bacterium (Lysinibacillus sp.) from Avicennia marina.
P2860
Q24680426-C5302B1C-19F2-4303-BFF8-A03149D8CA19Q33403252-84F5C69C-6D9D-4A33-A5CA-00544EA925B9Q33447691-83396E88-1265-4193-ABE6-8872CD46CE23Q33552027-390FCF59-166D-43C6-AC28-64E33F0ED034Q33694628-A75A9B3B-A3CE-4F09-B31E-2114AD691A2CQ34005421-637021FA-5CE3-4C00-90FB-D058FE63621EQ37018640-0F032462-927D-4E0B-A61D-2032A15D758DQ37194056-CB73C339-9E7E-4FC8-8560-2FF5CBBF68F4Q37205966-F9BC313B-1D74-48BF-A3D1-01413E86EEF4Q37398309-3887E784-6E7C-4D0A-9D6D-1E7DA6ED8A1AQ37586932-7B658925-DCD5-4AC7-B0BA-09CB690F977FQ37620826-EDA3A2BE-0F47-4539-8D7E-817081E1DE55Q37634016-743BCC68-CBF8-4783-A2FD-A44DC4237E1BQ37664729-549D20B8-ADD7-4795-B000-56335D8B8D0EQ37668317-24202614-B62B-4E0C-A1D1-FA1CC4A0FDF5Q38465134-5C1E45CD-B425-416E-B5D3-F59D3480A658Q38559463-9CEC25D5-BD9F-4948-94C8-125EB2239EFBQ38995206-78627FE9-33B6-44A4-B657-31F57DC52C73Q40117791-23F52A6F-BD08-434B-A10D-BB265646F4BBQ40533048-144D83F1-4120-420C-82A2-8DFC3DF43E1EQ42175440-BBF6C15A-B0FC-4F14-B3EC-8D4217AA8E5AQ43819145-796597DD-E7A8-4C62-95C6-69382A04F37BQ46782122-7DC3223F-FA0F-4E87-927E-0F33E4F501F6Q50056661-8735CBE7-E3D5-41C3-80EF-CBA66C6B0CD2Q51979076-67D44446-ACDC-4509-999C-97291A0B8C46Q54393906-BDCA1DD8-13CD-45AD-ABA5-2BCE0DEE26E2
P2860
Management options for adenosine deaminase deficiency; proceedings of the EBMT satellite workshop (Hamburg, March 2006).
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Management options for adenosi ...... orkshop (Hamburg, March 2006).
@ast
Management options for adenosi ...... orkshop (Hamburg, March 2006).
@en
type
label
Management options for adenosi ...... orkshop (Hamburg, March 2006).
@ast
Management options for adenosi ...... orkshop (Hamburg, March 2006).
@en
prefLabel
Management options for adenosi ...... orkshop (Hamburg, March 2006).
@ast
Management options for adenosi ...... orkshop (Hamburg, March 2006).
@en
P2093
P50
P1433
P1476
Management options for adenosi ...... orkshop (Hamburg, March 2006).
@en
P2093
H Bobby Gaspar
Luigi Notarangelo
Manfred Hoenig
Mike Hershfield
Rebecca Buckley
P304
P356
10.1016/J.CLIM.2006.12.009
P577
2007-02-14T00:00:00Z